UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-QSB
QUARTERLY REPORT PURSUANT TO SECTIOIN 13 OR 15 (D)
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE PERIOD ENDED: JANUARY 31, 2004
COMMISSION FILE NUMBER: 000-31727
THE QUANTUM GROUP, INC.
------------------------------------------------------
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
NEVADA 20-0774748
------------------------------ -------------------
STATE OR OTHER JURISDICTION OF (IRS EMPLOYER
INCORPORATION OR ORGANIZATION) IDENTIFICATION NO.)
12230 Forest Hill Blvd., Suite 157, Wellington, FL 33414
-------------------------------------------------------------
(ADDRESS, INCLUDING ZIP CODE, OF PRINCIPAL EXECUTIVE OFFICES)
(561) 227-1597
----------------------------------------------------
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)
INDICATE BY CHECK MARK WHETHER THE REGISTRANT (1) HAS FILED ALL DOCUMENTS AND
REPORTS REQUIRED TO BE FILED BY SECTIONS 13 OR 15(D) OF THE SECURITIES EXCHANGE
ACT OF 1934 DURING THE PRECEDING 12 MONTHS (OR FOR SUCH SHORTER PERIOD THAT THE
REGISTRANT WAS REQUIRED TO FILE SUCH REPORTS), AND (2) HAS BEEN SUBJECT TO SUCH
FILINGS FOR THE PAST 90 DAYS.
YES [X] NO [ ]
APPLICABLE ONLY TO CORPORATE ISSUERS:
As of February 29, 2004, the number of the Company's shares of par value $.001
common stock outstanding was 3,371,470.
INDEX
Part I - FINANCIAL INFORMATION
Item 1 - Financial Statements-Unaudited
Condensed Balance Sheet 3
Condensed Statements of Operations 4
Condensed Statement of Changes in Deficiency in Assets 5
Condensed Statements of Cash Flows 6
Notes to Condensed Consolidated Financial Statements 7
Item 2- Management's Discussion and Analysis of Financial Condition
And Results of Operations 11
Item 3- Controls and Procedures 13
PART II - OTHER INFORMATION 13
SIGNATURES 14
2
PART I
ITEM 1. FINANCIAL INFORMATION.
The Quantum Group, Inc.
Condensed Balance Sheet
( A Development Stage Enterprise)
January 31, 2004
(Unaudited)
ASSETS
Current assets:
Cash $ 1,706
---------
Total current assets 1,706
Property and equipment, net of accumulated depreciation of $3,257 1,577
Investment in related companies 10,000
Other assets 2,870
---------
Total assets $ 16,153
=========
LIABILITIES AND SHAREHOLDERS' DEFICIT
Current liabilities:
Accounts payable and accrued liabilities $ 196,777
Accrued payroll 142,633
Notes payable and accrued interest - shareholder (note 8) 250,700
---------
Total current liabilities 590,110
Commitments and contingencies
Deficiency in assets accumulated during development stage (573,957)
---------
Total liabilities and deficiency in assets $ 16,153
=========
See accompanying notes to condensed financial statements
3
The Quantum Group, Inc.
Condensed Statement of Operations
( A Development Stage Enterprise)
For the Periods Ended January 31, 2004 and 2003
(Unaudited)
For the period
For the three months ended July 24, 2001
------------------------------------ (inception) to
January 31, 2004 January 31, 2003 January 31, 2004
---------------- ---------------- ----------------
Interest Expense $ 9,356 $ 8,194 $ 42,795
Other Expenses 146,178 23,144 573,270
----------- ----------- -----------
Expenses Representing Net Loss $ 155,534 $ 31,338 $ 616,065
=========== =========== ===========
Basic and diluted loss per common share $ (0.05) $ (0.01) $ (0.22)
=========== =========== ===========
Weighted average number of common shares
outstanding 3,320,889 2,700,000 2,856,870
=========== =========== ===========
See accompanying notes to condensed financial statements
4
The Quantum Group, Inc.
Statement of Changes in Deficiency in Assets Accumulated
During the Development Stage
January 31, 2004
(Unaudited)
Common Stock Allocated
par value $.001 per Additional Shares
share 170,000,000 authorize Paid-in Deferred for Deferred Accumulated Total
# of Shares Amount Capital Compensation Compensation Deficit Equity
----------- ------ ------- ------------ ------------ ------- ------
Balance 7/24/01 (inception) 2,700,000 $ 2,700 $ 17,300 -- -- -- $ 20,000
Net (loss) -- -- -- -- -- $(127,576) (127,576)
--------- --------- --------- --------- --------- --------- ---------
Balance at 10-31-01 2,700,000 2,700 17,300 (127,576) (107,576)
Net (loss) -- -- -- -- -- (86,400) (86,400)
--------- --------- --------- --------- --------- --------- ---------
Balance at 10/31/02 2,700,000 2,700 17,300 -- -- (213,976) (193,976)
Merger with TPII 510,877 511 (121,363) -- -- -- (120,852)
Sale of common stock for cash 86,000 86 64,914 -- -- -- 65,000
Deferred compensation-stock options -- -- 207,500 (207,500) -- -- --
Deferred compensation-stock grants -- -- -- (327,150) 327,150 -- --
Amortization of deferred comp -- -- -- 3,458 -- -- 3,458
Net (loss) -- -- -- -- -- (246,555) (246,555)
--------- --------- --------- --------- --------- --------- ---------
Balance at 10/31/03 3,296,877 3,297 168,351 (531,192) 327,150 (460,531) (492,925)
Issuance of common stock - stk grants 71,260 71 64,056 64,127 (64,127) -- 64,127
Amortization of deferred comp -- -- -- 10,375 -- -- 10,375
Net (loss) -- -- -- -- -- (155,534) (155,534)
--------- --------- --------- --------- --------- --------- ---------
Balance at 1/31/04 3,368,137 $ 3,368 $ 232,407 $(456,690) $ 263,023 $(616,065) $(573,957)
========= ========= ========= ========= ========= ========= =========
See accompanying notes to condensed financial statements
5
The Quantum Group, Inc.
(A Development Stage Enterprise)
Statements of Cash Flow
For the Periods Ended January 31, 2004 and 2003
(Unaudited)
3 Months 3 Months July 24, 2001
ended ended (Inception) to
January 31, 2004 January 31, 2003 January 31, 2004
---------------- ---------------- ----------------
OPERATING ACTIVITIES
Net (loss) $(155,534) $ (31,339) (616,065)
--------- --------- ---------
Adjustments to reconcile net loss to net cash used
in operating activities:
Depreciation 330 311 3,257
Amortization of deferred compensation 74,502 -- 77,960
Changes in operating assets and liabilities:
(Increase) decrease in other assets (97) 1,820 (2,870)
Increase (decrease) in accounts payable and
accrued liabilities 68,177 26,195 261,345
--------- --------- ---------
Total adjustments 142,912 28,326 339,692
--------- --------- ---------
Net cash used in operating activities (12,622) (3,013) (276,373)
INVESTING ACTIVITIES
Purchase of property and equipment (214) -- (4,833)
Investment in related companies -- -- (10,000)
--------- --------- ---------
Net cash provided by (used in) investing activities (214) -- (14,833)
--------- --------- ---------
FINANCING ACTIVITIES
Proceeds from note payable 14,300 3,013 207,912
Proceeds from issuance of common stock -- -- 85,000
--------- --------- ---------
Net cash provided by financing activities 14,300 3,013 292,912
--------- --------- ---------
Net increase (decrease) in cash 1,464 -- 1,706
Cash at beginning of period 242 -- --
--------- --------- ---------
Cash at end of period $ 1,706 $ -- $ 1,706
========= ========= =========
Supplemental disclosures of cash flow information:
Cash paid during the period for interest $ -- $ -- $ --
Supplemental disclosures of non-cash investing and financing
activities:
Assumption of Liabilities of Transform Pack International, Inc. $ -- $ -- $ 120,852
See accompanying notes to condensed financial statements
6
THE QUANTUM GROUP, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO CONDENSED FINANCIAL STATEMENTS - (UNAUDITED)
JANUARY 31, 2004
NOTE 1: DESCRIPTION OF COMPANY
On May 28, 2003, Transform Pack International, Inc. (the "Company")
merged with Quantum HIPAA Consulting, Inc ("Quantum"). On January 30, 2004, the
shareholders of the Company approved the reincorporation of the Company under
the name of The Quantum Group, Inc. ("TQGI"). The shareholders approved a 1 for
10 reverse stock split (See Note 6). The Company is a development stage company
with no current revenues. The Company's business model is to become a provider
of services to the healthcare industry in three complementary areas: outsourcing
administrative responsibilities for physicians, Managed Care Organizations,
healthcare facilities and physician associations; developing new technologies
for the healthcare delivery system; and providing healthcare services to
consumers. (See Note 4)
GOING CONCERN
The Company has no revenues to date. Since its inception, the Company has been
dependent upon the receipt of capital investment to fund its continuing
activities. In addition to the normal risks associated with a new business
venture, there can be no assurance that the Company's business plan will be
successfully executed. The Company's ability to execute its business model will
depend on its ability to obtain additional financing and achieve a profitable
level of operations. There can be no assurance that sufficient financing will be
obtained. Nor can any assurance be made that the Company will generate
substantial revenues or that the business operations will prove to be
profitable. These conditions raise substantial doubt about the Company's ability
to continue as a going concern. The financial statements do not include any
adjustments that might result from the outcome of these uncertainties.
NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
CASH EQUIVALENTS
The Company considers all highly liquid debt instruments with original
maturities of three months or less to be cash equivalents. For the three month
period ended January 31, 2004 and 2003, there were no cash equivalents.
PROPERTY AND EQUIPMENT
Furniture and equipment are stated at cost. Depreciation is calculated using the
straight-line method over the estimated useful lives of the assets, which range
from three to five years.
RESEARCH AND DEVELOPMENT COSTS
Research and development costs are charged to expense when incurred.
USE OF ESTIMATES
The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and
the reported amount of revenues and expenses during the reporting period. Actual
results could differ from those estimates and the differences could be material.
7
THE QUANTUM GROUP, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO CONDENSED FINANCIAL STATEMENTS - (UNAUDITED)
JANUARY 31, 2004
NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
INCOME TAXES
The Company has not recognized any benefit of such net operating loss carry
forwards in the accompanying financial statements in accordance with the
provisions of SFAS No. 109, as the realization of this deferred tax benefit is
not likely. A 100% valuation allowance has been recognized to offset the entire
effect of the Company's net deferred tax asset.
STOCK COMPENSATION
The company has adopted Statement of Financial Accounting Standards No. 123
("SFAS 123"), "Accounting for Stock-Based Compensation." SFAS 123 encourages the
use of a fair-value-based method of accounting for stock-based awards, under
which the fair value of stock options is determined on the date of grant and
expensed over the vesting period. Under SFAS 123, companies may, however,
measure compensation costs for those plans using the method prescribed by
Accounting Principles Board Opinion No. 25 ("APB No. 25"), "Accounting for Stock
Issued to Employees." Companies that apply APB No. 25 are required to include
pro forma disclosures of net earnings and earnings per share as If the
fair-value-based method of accounting had been applied. The Company elected to
account for such plans under the provisions of APB No. 25. The Company accounts
for stock options granted to consultants under SFAS 123.
NOTE 3: FAIR VALUE OF FINANCIAL INSTRUMENTS
The carrying amounts of cash and cash equivalents, accounts payable and accrued
liabilities approximate their fair value because of the short maturity of these
financial instruments.
NOTE 4: MERGER WITH QUANTUM HIPAA CONSULTING, INC.
Effective May 28, 2003, the Company consummated a merger pursuant to a merger
agreement with Quantum HIPAA Consulting Group, Inc. Quantum HIPAA Consulting
Group, Inc developed a training compact disc and manuals to instruct the
healthcare industry on the implementation of the regulations created to comply
with the Health Insurance Portability and Accountability Act of 1996 (HIPAA).
The Company completed the merger by issuing 2,700,000 million shares of Common
Stock to the sole shareholder of Quantum, in exchange for all the issued and
outstanding shares of Quantum. For accounting purposes, the acquisition was
treated as a recapitalization of the Company. The value of the net assets of the
Company after the acquisition was completed is the same as their historic book
value.
On May 30 2003, in accordance with the agreement, the Company, Transform Pack
International, Inc., sold its wholly owned subsidiary, Transform Pack, Inc.
(TPI) to certain previous shareholders and investors of the Company. Transform
Pack, Inc. and its shareholders have agreed to assume and indemnify the Company
for all operating debts of the Company.
8
THE QUANTUM GROUP, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO CONDENSED FINANCIAL STATEMENTS - (UNAUDITED)
JANUARY 31, 2004
NOTE 5: LOSS PER SHARE
Basic loss per share is computed by dividing loss available to common
shareholders by the weighted average number of common shares for the period. The
computation of diluted loss per share is similar to basic loss per share, except
that the denominator is increased to include the number of additional common
shares that would have been outstanding if the potentially dilutive common
shares, such as options, had been issued. Diluted loss per share is not
presented as the effects would be anti-dilutive.
NOTE 6: OTHER COMMON STOCK TRANSACTIONS
DEFERRED COMPENSATION
On October 1, 2003, the Company granted 363,500 shares of common stock to
employees, directors and advisors in lieu of or as partial compensation for
services performed for the Company. These shares start vesting January 1, 2004
and are to be vested over two and three year periods. The Company recorded
$327,150 of unearned compensation and recorded the unvested shares as Deferred
Compensation - Allocated Shares in the equity section of the balance sheet. The
Company recognized $35,737 in compensation expense related to these stock grants
for the three month period ended January 31, 2004. The value of the stock was
determined by the closing market price at the date of grant. Additionally, the
Company granted 415,000 options at $.40 per share to employees and directors to
be vested over three years. The options start vesting January 1, 2004. The
Company has recognized $207,500 in deferred compensation in relation to the
issuance of the stock options in conjunction with Statement of Financial
Accounting Standard no. 123. The values of the options were determined based
upon the market value of the common shares at the time of grant less the
exercisable price. The Company has recognized $10,375 in compensation expense
related to these stock option grants for the three month period ended January
31, 2004.
REVERSE STOCK SPLIT
In January 2004, the shareholders of the Company approved the merger of the
Company into The Quantum Group, Inc. for the purpose of reincorporation in the
State of Nevada. In conjunction with the reincorporation, the shareholders
approved a 1 for 10 reverse stock split of its common stock. An amended and
restated Articles of Incorporation have been filed to change the name of the
Company to The Quantum Group, Inc. ("TQGI") and to set the authorized shares of
common stock to 170,000,000 at a par value of $.001 per share and authorized
preferred stock to 30,000,000 at a par value of $.001 per share. All share and
per share amounts have been retroactively restated in the accompanying financial
statements and notes for all periods presented.
9
THE QUANTUM GROUP, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO CONDENSED FINANCIAL STATEMENTS - (UNAUDITED)
JANUARY 31, 2004
NOTE 7: STOCK OPTIONS
In October 2003 the Company adopted a stock option plan. The purpose of the
stock option plan was to increase the employees and non-employee director's
proprietary interest in Quantum and to align more closely their interests with
the interests of the shareholders of Quantum, as well as to enable Quantum to
attract and retain the services of experienced and highly qualified employees
and non-employees directors.
Options granted under this plan may either be options qualifying as incentive
stock options under Section 422 of the Internal Revenue Code of 1986, as
amended, or options that do not so qualify. Any incentive option must provide
for an exercise price of not less than 100% of the fair market value of the
underlying shares on the date of such grant, but the exercise price of any
incentive option granted to an eligible employee owning more than 10% of the our
common stock must be at least 110% of such fair market value as determined on
the date of the grant.
The term of each option and the manner in which it may be exercised is
determined by the board of directors, provided that no option may be exercisable
more that 10 years after the date of its grant and, in the case of an incentive
option granted to an eligible employee owning more that 10% of the our common
stock, no more than five years after the date of the grant. The board of
directors shall determine the exercise price of non-qualified options.
The Company has reserved 5,000,000 shares of common stock under the plan. The
board of directors or a committee of the board of directors will administer the
plan including, without limitation, the selection of the persons who will be
granted plan options under the plan, the type of plan options to be granted, the
number of shares subject to each plan options and the plan option price.
The per share exercise price of shares granted under the plan may be adjusted in
the event of certain changes in the total purchase price payable upon the
exercise in full of options granted under the plan. Officers, directors and key
employees of and consultants to Quantum will be eligible to receive
non-qualified options under the plan. Only officers, directors and employees of
Quantum who are employed by Quantum or by any subsidiary thereof are eligible to
receive incentive options.
The Company has elected to account for the stock options under the Accounting
Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees," and
related interpretations. Accordingly, no compensation expense has been
recognized on the employee stock options. The Company accounts for stock options
granted to consultants under Financial Accounting Standards Board Statement No.
123, "Accounting for Stock-Based Compensation." The Company recognized $207,500
in compensation expense, of which $193,667 was deferred at January 31, 2004.
No options were granted during the three month periods ended January 31, 2004
and 2003, respectively.
10
THE QUANTUM GROUP, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO CONDENSED FINANCIAL STATEMENTS - (UNAUDITED)
JANUARY 31, 2004
NOTE 7: STOCK OPTIONS (CONTINUED)
A summary of options during the years ended January 31, 2004 and 2003 is shown
below:
Weighted Weighted
Average Average
Number of Exercise Number of Exercise
Shares Price Shares Price
Outstanding at beginning of the period 415,000 $0.40 -- $ --
Granted -- $ -- -- $ --
Exercised -- $ -- -- $ --
Forfeited -- $ -- -- $ --
--------------------- -------------------
Outstanding at January 31, 415,000 $0.40 -- $ --
--------- -----
Exercisable at January 31, -- --
Available for issuance at January 31, 5,000,000 --
--------- -----
Had the compensation expense for the stock option plan been determined based on
the fair value of the options at the grant date consistent with the methodology
prescribed under Statement of Financial Standards No. 123, "Accounting for Stock
Based Compensation," at January 31, the Company's net income and earnings per
share would have been reduced to the pro forma amounts indicated below:
Net income (loss)
As reported $(155,534) $(31,339)
Pro forma $(163,834) $(31,339)
Earnings per share
As reported $ (0.05) $ (0.01)
Pro forma $ (0.05) $ (0.01)
The fair value of each option is estimated on the date of grant using the fair
market value option-pricing model with the assumptions:
Risk-free interest rate 4%
Expected life (years) 5
Expected volatility 2.31
Expected dividends None
11
THE QUANTUM GROUP, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO CONDENSED FINANCIAL STATEMENTS - (UNAUDITED)
JANUARY 31, 2004
NOTE 8: RELATED PARTY TRANSACTIONS
On November 1, 2002, the Company entered into an agreement with a shareholder to
purchase certain intellectual property integral to the Company's business. In
exchange, the company issued a three (3) year installment note for $179,080 with
an interest rate of eighteen percent (18%) per annum. The price of the sale was
equal to the cost the shareholder incurred to develop the property purchased.
The note is payable monthly starting January 2003. The Company is in technical
default as no payments have been made on the note. The Company is accruing
interest, at 18% per annum, monthly on the unpaid principal balance and has
classified the note as current as per the agreement. The interest accrued at
January 31, 2004 is $40,293.
On November 2, 2002 the Company signed a demand note, with an interest rate of
eighteen percent (18%) per annum, for the expenses a shareholder paid on behalf
of the Company subsequent to the sale of the intellectual property. The note
payable balance and accrued interest as of January 31, 2004 and 2003 are $28,832
and $2,495 respectively.
In July 2003, the Company purchased a 20% interest Renaissance Health Systems,
Inc. for $5,000 from a shareholder of the Company. Renaissance Health Systems is
a development stage enterprise in the health care business. Additionally, the
Company purchased a 20% interest in Quantum Medical Technologies, Inc. for
$5,000 from a shareholder of the Company. Quantum Medical Technologies, Inc. is
a development stage enterprise in the medical technologies business.
NOTE 9: SUBSEQUENT EVENTS
Following a motion approved by the Company shareholders during a meeting January
30, 2004, in February 2004, the Board of Directors agreed to issue 13,300,000
post reverse shares to the shareholders of both Quantum Medical Technologies,
Inc. (QMT) and Renaissance Health Systems, Inc. (RHS) for the 80% of the those
companies which the Company does already not own. Control in the Company will
not change, since all the shareholders in numbers and relative beneficial
ownership of both QMT and RHS are also material and beneficial owners of the
common shares of the Company today. The final merger is not expected to be
consummated until documentation is completed and approval of the Board of
Directors of all the companies.
12
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS.
GENERAL
The discussion and analysis set forth below should be read in conjunction with
our Financial Statements and the related notes thereto appearing elsewhere in
this quarterly report. The information presented for the three months ended
January 31, 2004 and January 31, 2003, was derived from unaudited financial
statements, which, in our opinion, reflect all adjustments (consisting only of
normal recurring adjustments) necessary for a fair presentation.
FORWARD LOOKING STATEMENTS
This Report on Form 10-QSB contains certain forward-looking statements. When
used in this report, press releases and elsewhere by the management of the
Company from time to time, the words "believes", "anticipates", and "expects"
and similar expressions are intended to identify forward-looking statements that
involve certain risks and uncertainties. Additionally, certain statements
contained in this discussion may be deemed forward-looking statements that
involve a number of risks and uncertainties. Among the factors that could cause
actual results to differ materially are the following: the ability of the
Company to meet its working capital and liquidity needs, economic trends for
consumer advertisers, the availability of long-term credit, unanticipated
changes in the U.S. and international economies, business conditions and growth
in e-commerce and the timely development and acceptance of new products, the
impact of competitive products and pricing, and other risks detailed from time
to time in the Company's SEC reports. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
hereof. The Company undertakes no obligation to publicly release the results of
any events or circumstances after the date hereof or to reflect the occurrence
of unanticipated events.
GOING CONCERN
The Company is a development stage company that over the last two years has
expensed material sums in creating procedures, manuals and systems to assist the
medical community in the implementation of medical regulations. Though the
Company has materially finished developing its training programs, additional
updates and deployment will be required.
As shown in the accompanying condensed consolidated financial statements, the
Company has incurred recurring losses and negative cash flows from its
development and organization activities and has negative working capital and
shareholders' deficit. Under normal conditions, these conditions raise
substantial doubt about the Company's ability to continue as a going concern.
There can be no assurance that the Company will be able to successfully
implement its plans to generate additional investor interest and raise
additional capital, or if such plans are successfully implemented, that the
Company will achieve its goals.
Furthermore, if the Company is unable to raise additional funds, it may be
required to modify its growth and developmental plans, and even be forced to
severely limit development operations completely.
13
The accompanying condensed consolidated financial statements have been prepared
assuming that the Company will continue as a going concern and do not include
any adjustments to reflect the possible future effects of the recoverability and
classification of assets or the amounts and classification of liabilities that
might result from the outcome of this uncertainty. See "Liquidity and Capital
Resources," below.
RESULTS OF OPERATIONS
Three months ended January 31, 2004 and 2003
The expenses for the quarter ended January 31, 2004 were $155,534 compared to
$31,338 for the quarter January 31, 2003. The increase was primarily due to an
increase in salaries and consulting fees as a result of the amortization of
deferred compensation of $74,502.
LIQUIDITY AND CAPITAL RESOURCES
At January 31, 2004, the Company had working capital deficit of $588,404 as
compared to a working capital deficit of $227,076 at January 31, 2003.
Cash inflow from financing activities was $14,300 for the three months ended
January 31, 2004, compared $3,013 for the three months ended January 31, 2003.
The increase was due to additional funds advanced by the majority shareholder.
The Company will need to secure financing during the next 12 months.
The Company's development plan is to identify, negotiate with and acquire
business and services that will allow the Company to provide comprehensive
consulting services, technological, strategic intelligence and systems that will
allow the small to medium size medical organization to provide better care,
better medical outcomes and earn more profit. The Company expect to acquire the
candidate businesses after extensive due diligence, and then to acquire the
business enterprise including cash flow by issuing stock, notes and cash. The
Company expects to secure financing for the acquisition by selling common and/or
preferred shares, issuing debt or notes and by leveraging the potential
acquisition. There is no assurance that the Company will be able to execute on
its plans and clearly, additional financing will be needed to develop and
implement its business plan.
14
ITEM 3. CONTROLS AND PROCEDURES
Our Management and resources are limited, as of January 31, 2004 we had only
three full time employees who were also officers and directors of the Company.
These positions are President/CEO, CFO and a Vice President of Administration,
collectively these officers have conducted an evaluation of the effectiveness of
our disclosure controls and procedures (as defined in Rule 13a-15(e) and
15d-15(e) promulgated under the Securities and Exchange Act of 1934, as amended)
as of the end of the fiscal quarter covered by this report. Based upon that
evaluation and both our limited developmental history as well as the size of our
organization, our management has concluded that we have adequate disclosure
controls. However we must improve procedures for effective and timely gathering,
analyzing and disclosing the information we are required to disclose in our
reports filed under the Securities Exchange Act of 1934, as amended. Management
expects to add additional controls and personnel in the near future as capital
becomes available. There have been no significant changes made in our internal
controls or in other factors that could significantly affect our internal
controls during the fiscal quarter covered by this report.
PART II
OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
The Company is not a party to any litigation.
ITEM 2. CHANGES IN SECURITIES
None
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
As of June 30, 2003, the Company is in default of a $ 179,080 obligation to the
Company's President and largest shareholder. He has not declared the note in
default as of this time.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY-HOLDERS
On January 30, 2004 the Company held a special meeting of the shareholders. The
shareholder present, voted to accept following by a vote of 2,700,000 to 0
(668,137 did not vote):
1. Change the state of incorporation from Minnesota to Nevada and the
merger with and into The Quantum Group, Inc. and the change of the
corporate name from Transform Pack International, Inc. to The Quantum
Group, Inc.
2. A 1 for 10 reverse stock split
3. An amendment to the Articles of Incorporation to increase the
authorized shares outstanding from 40,000,000 to 170,000,000 and to
increase the authorized preferred stock from 5,000,000 to 30,000,000.
4. Acceptance of the 2003 Equity & Option Plan
15
5. The current Board of Directors; Noel J. Guillama, Susan Guillama,
Donald B. Cohen, James D. Baker, Mark Haggerty, Marion D. Thorpe, were
re-elected to another one term
6. Approval and ratify the Board of Directors action on the issuance of
363,500 common shares and 415,000 options to management, directors and
advisors.
7. Approval of the acquisition of the remaining 80% of Renaissance Health
Systems, Inc. and the remaining 80% of Quantum Medical Technologies,
Inc. which the Company does not own by issuing 13,300,000 shares upon
the ratification by the Board of Directors.
ITEM 5. OTHER INFORMATION
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.
None
Exhibits: Copies of the following documents are included or furnished as
exhibits to this report pursuant to Item 601 of Regulation S-B.
Exhibit Title of Document
No.
31.1 Certification of the Chief Executive Officer pursuant to Section 302
of the Sarbanes-Oxley Act of 2002
31.2 Certification of the Chief Financial Officer pursuant to Section 302
of the Sarbanes-Oxley Act of 2002
32.1 Certification of the Chief Executive Officer pursuant to Section 906
of the Sarbanes-Oxley Act of 2002
32.2 Certification of the Chief Financial Officer pursuant to Section 906
of the Sarbanes-Oxley Act of 2002
16
SIGNATURE
In accordance with the requirements of the Securities Exchange Act of 1934, the
Registrant has caused this report to be signed on its behalf by the undersigned,
duly authorized.
THE QUANTUM GROUP, INC.
Date:
BY: /s/ Noel J. Guillama
-----------------------------------------
Noel J. Guillama, President
17